Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is lung cancer?
The lungs are two sponge-like organs that bring oxygen into the body and remove carbon dioxide. Lung cancer starts when cells lining the airways or air sacs grow uncontrollably, forming a tumor that can block breathing, invade nearby tissue, and spread elsewhere. Smoking is the biggest cause, but lung cancer also occurs in people who never smoked. Caught early — often through low-dose CT screening — small lung cancers can frequently be cured without surgery.
The main types
Doctors group lung cancer by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Non-small cell lung cancer (NSCLC) | About 85% of cases. Includes adenocarcinoma (most common, often in non-smokers and outer lung), squamous cell, and large-cell types. |
| Small cell lung cancer (SCLC) | About 15% of cases; grows and spreads fast and is strongly linked to smoking, but responds quickly to chemo and radiation. |
| Lung carcinoid (neuroendocrine) tumor | A rarer, usually slow-growing type that often behaves more gently. |
Staging, in plain terms
Staging describes how big the tumor is and how far it has traveled, using T (tumor size and location), N (lymph nodes involved), and M (metastasis/distant spread). Small cell lung cancer is often also described simply as 'limited' (one side of the chest) or 'extensive' (beyond it).
| TNM | What it generally means |
|---|---|
| Stage 0 | Earliest, non-invasive cancer confined to the airway lining. |
| Stage I | A small tumor still inside the lung, with no lymph-node spread. Often curable with surgery or focused radiation. |
| Stage II | A larger tumor and/or spread to nearby lymph nodes within the lung. |
| Stage III | Locally advanced — spread to lymph nodes in the center of the chest, but not to distant organs. Usually treated with combined therapies. |
| Stage IV | Spread to the other lung, the fluid around the lung, or distant organs. Very treatable with modern medicines, often for years. |
The standard of care
Lung Cancer is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery
For early NSCLC, removing the tumor (a lobe or smaller wedge of lung) offers a strong chance of cure when a patient is healthy enough for an operation.
Radiation therapy
Stereotactic radiation (SBRT) can cure early tumors without surgery; for stage III, radiation combined with chemotherapy is a standard cure-focused treatment.
Systemic medicine
Chemotherapy, targeted pills matched to tumor mutations (such as EGFR or ALK), and immunotherapy that unleashes the immune system — chosen by the tumor's molecular profile.
How radiation treatment works
Radiation uses focused high-energy x-rays to damage cancer-cell DNA so the cells can no longer divide. Healthy cells repair this damage better than cancer cells, so treatment clears cancer while sparing normal tissue. With SBRT, advanced imaging tracks the tumor as it moves with each breath, so the beams stay locked on a small target. Sessions are painless and brief; common side effects are some fatigue, and occasionally a temporary cough, sore throat, or mild swallowing discomfort that settle after treatment.
The main ways radiation is delivered for lung cancer:
Stereotactic body radiation therapy (SBRT)
Delivers a few very precise, high-dose treatments (often 3-5 sessions) to a small early tumor. Cure rates rival surgery for stage I cancer, and it is the standard option when surgery is too risky.
Conventional/curative external-beam (IMRT/IGRT)
Shapes the dose to larger or more central tumors over several weeks, usually alongside chemotherapy for stage III disease, while sparing the heart, normal lung, and spinal cord.
Prophylactic & palliative radiation
In small cell lung cancer, low-dose brain radiation can prevent spread; targeted radiation also relieves symptoms like pain, bleeding, or airway blockage.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
SBRT for inoperable early lung cancer: Long-term data confirm stereotactic radiation controls more than 90% of stage I tumors locally and is now a standard curative option for patients who cannot have surgery.[1]
RTOG 0236 and pooled SBRT series · PMID 20233825 (opens in a new tab)
Durvalumab after chemoradiation (PACIFIC): Adding a year of immunotherapy after chemo-plus-radiation for stage III NSCLC substantially improved survival and reset the standard of care.[2]
PACIFIC trial, NEJM · PMID 28885881 (opens in a new tab)
Low-dose CT screening saves lives: Yearly low-dose CT scans for people at high risk cut lung-cancer deaths by 20-24% by catching tumors when they are small and curable.[3]
National Lung Screening Trial; NELSON · PMID 21714641 (opens in a new tab)
Common questions
I never smoked — can I still get lung cancer? Yes. A meaningful share of lung cancers, especially adenocarcinoma, occur in people who never smoked. Causes can include radon, secondhand smoke, air pollution, and inherited gene changes.
Can lung cancer be cured without surgery? Often, yes. For early tumors, stereotactic radiation (SBRT) offers cure rates close to surgery in just a few painless sessions.
Should I be screened? If you are roughly 50-80, smoke or recently quit, and have a significant smoking history, a yearly low-dose CT scan can catch cancer early. Ask your doctor whether you qualify.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.
- Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070-1076. (opens in a new tab) PMID 20233825 ↩
- Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929. (opens in a new tab) PMID 28885881 ↩
- National Lung Screening Trial Research Team; Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. Companion trial: de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 2020;382(6):503-513 (PMID 31995683). (opens in a new tab) PMID 21714641 ↩
